MSA-01 in Multiple System Atrophy
The purpose of this study is to evaluate whether MSA-01 slows the progression of multiple system atrophy (MSA) and to assess its safety. The primary question is: • Does MSA-01 slow the progression of motor impairment as measured by UMSARS Part 2 score? Participants will be randomly assigned to receive MSA-01 or placebo for 12 months. They will attend regular clinic visits for safety and efficacy assessments and record their medication use and any side effects in a diary.
Patients diagnosed as 'clinically established' or 'clinically probable' MSA base... [+3]
Patients with severe neurological disorders, other progressive movement disorder... [+4]